GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: BPN-14967 | BPN14967 | compound 81 [WO2015168286] | LBS-008 | LBS008
Compound class:
Synthetic organic
Comment: Tinlarebant (LBS-008; formerly BPN-14967) is an orally bioactive retinol binding protein 4 (RBP4) antagonist. It is proposed to reduce accumulation of lipofuscin (which contains cytotoxic bisretinoids) that drives degenerative retinal diseases [1,3].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Chou HD, Hwang YS, Chen KJ, Wu WC, Liu L, Ou ST, Liao W, Wang CC, Lin T, Lai CC. (2023)
Analysis of Retinol Binding Protein 4 and ABCA4 Gene Variation in Non-Neovascular Age-Related Macular Degeneration. Diagnostics (Basel), 13 (14). [PMID:37510153] |
|
2. Cioffi C, Johnson G, Allikmets R, Chen P, Conlon M, Zhu L. (2015)
Substituted 4-phenylpiperidines, their preparaiton and use. Patent number: WO2015168286A1. Assignee: Trustees Of Columbia University In The City Of New York, Petrukhin K, Freeman E. Priority date: 29/04/2015. Publication date: 05/11/2015. |
|
3. Petrukhin K. (2013)
Pharmacological inhibition of lipofuscin accumulation in the retina as a therapeutic strategy for dry AMD treatment. Drug Discov Today Ther Strateg, 10 (1): e11-e20. [PMID:25152755] |